A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered subcutaneously in HIV-seropositive patients.
Condition or disease
Biological: P3C541b Lipopeptide
Patients are randomized to receive P3C541b or placebo within each of two study groups. Enrollment in the first group will be independent of HLA type, whereas all but two of the patients enrolled in group 2 must have one or more HLA types A33, B8, B27, or Bw62. Treatment in group 2 will not begin until those in group 1 have reached day 14 without serious toxicity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
CD4 count >= 500 cells/mm3.
No evidence of AIDS, persistent diarrhea, fever, oral hairy leukoplakia, herpes varicella-zoster (multidermatomal), oral candidiasis, opportunistic infections, severe cytomegalovirus infection, or disseminated or chronic herpes simplex.
Successful establishment of EBV transformed B lymphoblastoid cell line.
Most patients in group 2 must possess one or more HLA types A33, B8, B27, or Bw62.
Patients with the following symptoms or conditions are excluded:
Positive circulating hepatitis B virus antigen.
Active clinically significant medical problems.
Evidence of psychiatric, medical, or substance abuse problems that would affect ability to participate on study.
Occupational or other responsibilities that would prevent completion of study.
Other HIV immunotherapeutic.
Zidovudine or analog.
Investigational therapies for HIV.
Patients with the following prior conditions are excluded:
History of cancer unless surgically excised with reasonable assurance of cure.
History of anaphylaxis or other serious adverse reactions to vaccines.
History of serious allergic reaction to any substance that required hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasms, or hypotension).
History of autoimmune disease or use of immunosuppressive medications.
History of suicide attempts or past psychosis.
Excluded within the past 6 months:
Zidovudine or analog.
Investigational therapies for HIV. Illicit drug use within past 30 days.